Genetic variation may impact on patient responses to anti-VEGF therapies

New research, published in the journal Clinical Ophthalmology (Kitchens et al, 2013: 7, 1987-1993), suggests that certain genetic variations in the VEGF-A, complement factor H and LOC387715 genes may predict patient response to anti-VEGF therapies. Researchers from Retina Associates of Kentucky and the Department of Medical & Molecular Genetics, Indiana University School of Medicine, undertook the research to determine if subgroups of wet AMD patients could be identified that have either optimal or little benefit from anti-VEGF treatment. Based on optical coherence tomography (OCT) analysis, patients carrying the LOC387715 A69STT genotype were significantly more likely to be classified as a non-responder when compared to patients with the GG and GT phenotypes.